Association of ADIPOR2 with liver function tests in type 2 diabetic subjects

Obesity

Volumn 16, Issue 10, 2008, Pages 2308-2313

  López Bermejo, Abel ^a,b   Botas Cervero, Patricia ^c   Ortega Delgado, Francisco ^a,b,d   Delgado, Elías ^e   García Gil, Maria M ^b   Funahashi, Tohru ^f   Ricart, Wifredo ^a,b,d   Fernández Real, José M ^a,b,d  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c San Agustin Hospital   (Spain)

^d Instituto de Salud Carlos III   (Spain)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR; ADIPONECTIN, HUMAN; ADIPOR1 PROTEIN, HUMAN; ADIPOR2 PROTEIN, HUMAN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

AGED; ARTICLE; BLOOD; CROSS-SECTIONAL STUDY; FEMALE; GENETICS; HUMAN; INSULIN RESISTANCE; LIVER; LIVER DISEASE; LIVER FUNCTION TEST; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN;

ADIPONECTIN; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADIPONECTIN; SPAIN;

EID: 53849117758     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2008.344     Document Type: Article

References (33)

1. Xu A, Wang Y, Keshaw H et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91-100.
2. Kamada Y, Tamura S, Kiso S et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003;125:1796-1807.
3. Hui JM, Hodge A, Farrell GC et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004;40:46-54.
4. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-1017.
5. Promrat K, Lutchman G, Uwaifo GI et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-196.
6. Bajaj M, Suraamornkul S, Piper P et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004;89:200-206.
7. Yamauchi T, Kamon J, Ito Y et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762-769.
8. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-451.
9. Vuppalanchi R, Marri S, Kolwankar D, Considine RV, Chalasani N. Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J Clin Gastroenterol 2005;39:237-242.
10. Kaser S, Moschen A, Cayon A et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005;54:117-121.
11. Wang H, Zhang H, Jia Y et al. Adiponectin receptor 1 gene (ADIPOR1) as a candidate for type 2 diabetes and insulin resistance. Diabetes 2004;53:2132-2136.
12. Hara K, Horikoshi M, Kitazato H et al. Absence of an association between the polymorphisms in the genes encoding adiponectin receptors and type 2 diabetes. Diabetologia 2005;48:1307-1314.
13. Damcott CM, Ott SH, Pollin TI et al. Genetic variation in adiponectin receptor 1 and adiponectin receptor 2 is associated with type 2 diabetes in the Old Order Amish. Diabetes 2005;54:2245-2250.
14. Stefan N, Machicao F, Staiger H et al. Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. Diabetologia 2005;48:2282-2291.
15. Vaxillaire M, Dechaume A, Vasseur-Delannoy V et al. Genetic analysis of ADIPOR1 and ADIPOR2 candidate polymorphisms for type 2 diabetes in the Caucasian population. Diabetes 2006;55:856-861.
16. Lopez-Bermejo A, Botas P, Funahashi T et al. Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin Endocrinol (Oxf) 2004;60:256-263.
17. Botas Cervero P, Delgado Alvarez E, Castano Fernandez G et al. Prevalence of diabetes mellitus and glucose intolerance in the population aged 30 to 75 years in Asturias, Spain. Rev Clin Esp 2002;202:421-429.
18. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(Suppl 1):S5-S20.
19. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
20. Bonora E, Targher G, Alberiche M et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63.
21. Crimmins NA, Martin LJ. Polymorphisms in adiponectin receptor genes ADIPOR1 and ADIPOR2 and insulin resistance. Obes Rev 2007;8:419-423.
22. Qi L, Doria A, Giorgi E, Hu FB. Variations in adiponectin receptor genes and susceptibility to type 2 diabetes in women. A tagging-single nucleotide polymorphism haplotype analysis. Diabetes 2007;56:1586-1591.
23. Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006;55:2871-2875.
24. Anania FA. Adiponectin and alcoholic fatty liver: is it, after all, about what you eat? Hepatology 2005;42:530-532.
25. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol 2006;101:2629-2640.
26. Yamauchi T, Nio Y, Maki T et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007;13:332-339.
27. Sun X, Han R, Wang Z, Chen Y. Regulation of adiponectin receptors in hepatocytes by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Diabetologia 2006;49:1303-1310.
28. Tsuchida A, Yamauchi T, Ito Y et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 2004;279:30817-30822.
29. Civitarese AE, Jenkinson CP, Richardson D et al. Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of Type 2 diabetes. Diabetologia 2004;47:816-820.
30. Vasseur F. Adiponectin and its receptors: partners contributing to the "vicious circle" leading to the metabolic syndrome? Pharmacol Res 2006;53:478-481.
31. Liu Y, Michael MD, Kash S et al. Deficiency of adiponectin receptor 2 reduces diet-induced insulin resistance but promotes type 2 diabetes. Endocrinology 2007;148:683-692.
32. Bjursell M, Ahnmark A, Bohlooly-Y M et al. Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes 2007;56:583-593.
33. Collins SC, Luan J, Thompson AJ et al. Adiponectin receptor genes: mutation screening in syndromes of insulin resistance and association studies for type 2 diabetes and metabolic traits in UK populations. Diabetologia 2007;50:555-562.